Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Centene Corporation (CNC)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
71.05-0.37 (-0.52%)
At close: 04:02PM EST
71.53 +0.48 (+0.68%)
After hours: 07:39PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Intermediate-term KST

Intermediate-term KST

Previous Close71.42
Open71.71
Bid69.29 x 1000
Ask71.85 x 800
Day's Range70.31 - 72.55
52 Week Range57.16 - 77.65
Volume3,440,288
Avg. Volume3,785,479
Market Cap41.458B
Beta (5Y Monthly)0.49
PE Ratio (TTM)56.89
EPS (TTM)1.25
Earnings DateFeb 07, 2022 - Feb 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est83.53
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
2% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for CNC

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Centene Corporation
    Analyst Report: Centene CorporationCentene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. After acquiring WellCare in early 2020, Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
Advertisement
Advertisement